Tran Cam T L, Leiper James M, Vallance Patrick
Centre for Clinical Pharmacology and Therapeutics, BHF Laboratories, Division of Medicine, University College London, 5 University Street, London, WC1E 6JJ, UK.
Atheroscler Suppl. 2003 Dec;4(4):33-40. doi: 10.1016/s1567-5688(03)00032-1.
An increasing number of reports in the literature indicate that endogenously produced inhibitors of nitric oxide synthase (NOS), particularly asymmetric dimethylarginine (ADMA) regulate nitric oxide generation in numerous disease states. Two dimethylarginine dimethylaminohydrolase (DDAH) enzymes metabolise ADMA. We and others have postulated that activity of DDAH is a key determinant of ADMA levels in vivo. This review summarises recent advances in the regulation and function of DDAH enzymes and its role in the regulation of nitric oxide generation.
文献中越来越多的报告表明，内源性产生的一氧化氮合酶（NOS）抑制剂，尤其是不对称二甲基精氨酸（ADMA），在多种疾病状态下调节一氧化氮的生成。两种二甲基精氨酸二甲胺水解酶（DDAH）可代谢ADMA。我们和其他人推测，DDAH的活性是体内ADMA水平的关键决定因素。这篇综述总结了DDAH酶在调节和功能方面的最新进展及其在一氧化氮生成调节中的作用。
